Comprehensive Pharmacology of Antitubercular Chemotherapy Drugs

Introduction/Overview

Antitubercular chemotherapy remains the cornerstone of treatment for Mycobacterium tuberculosis infections. The emergence of multidrug‑resistant and extensively drug‑resistant strains has intensified the need for a robust understanding of drug pharmacology among clinicians and pharmacists. This chapter aims to provide a systematic review of the principal antitubercular agents, with emphasis on their pharmacodynamics, pharmacokinetics, therapeutic strategies, safety profiles, and special clinical considerations.

Learning objectives following this chapter include:

• Identify the major drug classes employed in antitubercular therapy.
• Explain the molecular mechanisms that underlie the activity of first‑line and second‑line agents.
• Apply pharmacokinetic principles to optimize dosing regimens, particularly in patients with organ impairment.
• Recognize common and serious adverse events associated with antitubercular therapy and propose management strategies.
• Integrate drug interaction knowledge into clinical decision‑making for patients undergoing multidrug therapy.

Classification

First‑Line Agents

First‑line antitubercular drugs are the foundation of standard regimens and are characterized by high bactericidal activity against actively replicating bacilli. The four principal agents are:

• Isoniazid (INH): a hydrazide that inhibits mycolic acid synthesis.
• Rifampin (RIF): a rifamycin that blocks RNA synthesis.
• Pyrazinamide (PZA): an acid‑activated pyrazine derivative that disrupts membrane energetics.
• Ethambutol (EMB): an antimycobacterial that interferes with cell wall arabinogalactan synthesis.

Second‑Line and Adjunctive Agents

Second‑line drugs are reserved for drug‑resistant disease, adverse reactions, or intolerance of first‑line agents. They include:

• Fluoroquinolones (e.g., levofloxacin, moxifloxacin): inhibit DNA gyrase.
• Aminoglycosides (e.g., amikacin, kanamycin): bind the 30S ribosomal subunit.
• Linezolid: binds the 50S ribosomal subunit.
• Cycloserine, PAS (para‑aminosalicylic acid): inhibit cell wall synthesis.
• Ethionamide: blocks mycolic acid synthesis through a mechanism similar to isoniazid.

Chemical Classification

Antitubercular agents can be grouped chemically as follows:

• Hydrazides (isoniazid, ethionamide).
• Rifamycins (rifampin).
• Pyrazine derivatives (pyrazinamide).
• Quinolones (fluoroquinolones).
• Aminoglycosides (amikacin, kanamycin).
• Oxazolidinones (linezolid).
• Other miscellaneous molecules (ethambutol, cycloserine).

Mechanism of Action

Isoniazid

INH is pro‑drug that requires activation by the mycobacterial catalase‑peroxidase enzyme KatG. Activated INH forms a complex with NAD⁺ and then covalently inhibits InhA, an enoyl‑acyl carrier protein reductase essential for fatty acid elongation during mycolic acid synthesis. The blockade of mycolic acid incorporation compromises cell wall integrity, leading to bactericidal activity against actively dividing bacilli.

Rifampin

RIF binds to the β subunit of the bacterial RNA polymerase holoenzyme, obstructing the initiation of RNA synthesis. This inhibition results in decreased transcription of essential genes, thereby exerting bactericidal effects. RIF is particularly effective against rapidly dividing organisms but also displays bacteriostatic activity against dormant bacilli due to its ability to penetrate macrophages.

Pyrazinamide

PZA is converted intracellularly to pyrazinoic acid (POA) by the enzyme pyrazinamidase. POA accumulates in acidic compartments, such as lysosomes, and disrupts membrane proton gradients, ultimately compromising the proton motive force required for ATP synthesis. This mechanism is especially potent against semi‑dormant bacilli residing in acidic phagosomes.

Ethambutol

EMB competitively inhibits arabinosyl transferases (EmbA, EmbB, EmbC) involved in the synthesis of arabinogalactan, a critical component of the mycobacterial cell wall. The resultant cell wall defect reduces bacillary viability, particularly in the early phase of therapy.

Fluoroquinolones

Fluoroquinolones inhibit bacterial DNA gyrase (GyrA, GyrB) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By stabilizing the DNA‑enzyme complex and preventing re-ligation, these drugs induce double‑strand breaks that are lethal to the bacterium.

Aminoglycosides

These agents bind the 30S ribosomal subunit, causing misreading of mRNA and halting protein synthesis. Because of the requirement for oxygen‑dependent uptake, aminoglycosides are most effective against actively metabolizing bacilli but are limited by nephrotoxicity and ototoxicity.

Linezolid

Linezolid binds to the 50S subunit of the bacterial ribosome, inhibiting the formation of the 70S initiation complex. This interference with protein synthesis results in a bacteriostatic effect against many mycobacterial species, although clinical resistance is rare.

Pharmacokinetics

Absorption

Most antitubercular agents are orally administered and exhibit variable absorption profiles. Isoniazid demonstrates high oral bioavailability (>90%) with peak plasma concentrations (C_max) achieved within 1–2 h. Rifampin shows moderate bioavailability (≈60–70%) and a C_max occurring 1–3 h post‑dose. Pyrazinamide is well absorbed, with a C_max at 1–2 h, while EMB shows limited absorption (80%). Aminoglycosides are typically administered parenterally due to negligible oral absorption.

Distribution

Distribution volumes (V_d) vary significantly. INH has a V_d of ≈0.3 L kg⁻¹, indicating limited tissue penetration. RIF distributes widely (V_d ≈1.5 L kg⁻¹) and penetrates well into granulomatous lesions. PZA distributes into most tissues, including the central nervous system, with a V_d of 0.6–1.2 L kg⁻¹. EMB exhibits moderate tissue penetration (V_d ≈0.5 L kg⁻¹). Fluoroquinolones achieve high tissue concentrations, especially in macrophage‑rich environments. Aminoglycosides exhibit low tissue penetration, concentrating primarily in serum and renal tubular cells.

Metabolism

Metabolic pathways differ among agents. INH is primarily acetylated in the liver by N‑acetyltransferase 2 (NAT2), leading to inter‑individual variability in clearance. RIF induces hepatic enzymes, notably CYP3A4, and is metabolized by glucuronidation. PZA undergoes deamidation to POA, with subsequent conjugation. EMB is metabolized by hepatic glucuronidation. Fluoroquinolones are largely excreted unchanged but undergo minor hepatic metabolism via CYP3A4. Aminoglycosides are not metabolized and rely on renal excretion.

Excretion

Renal excretion constitutes the primary elimination route for many antitubercular drugs. INH is eliminated via renal excretion of both acetylated and non‑acetylated forms. RIF is excreted in bile and feces. PZA is cleared renally, with a half‑life (t_1/2) of ≈4–5 h. EMB is eliminated primarily by the kidneys, with a t_1/2 of ≈3–4 h. Fluoroquinolones are predominantly renally excreted (≈30–70%). Aminoglycosides require dose adjustment in renal impairment to avoid accumulation and toxicity.

Half‑Life and Dosing Considerations

The elimination half‑life of INH is approximately 0.5–1.5 h in fast acetylators and up to 6–8 h in slow acetylators, necessitating twice‑daily dosing to maintain therapeutic levels. RIF has a t_1/2 of 3–5 h, allowing once‑daily dosing. PZA’s t_1/2 is 2–4 h, but a higher loading dose may be necessary to achieve adequate concentrations. EMB’s t_1/2 is 2–3 h; thus, twice‑daily dosing is common. Fluoroquinolones typically have t_1/2 values ranging from 4–8 h, permitting once‑daily regimens. Aminoglycosides require careful timing of trough levels to guide dosing intervals, often every 12–24 h.

Therapeutic Uses/Clinical Applications

First‑Line Regimens

Standard first‑line therapy comprises a 2‑month intensive phase with INH, RIF, PZA, and EMB, followed by a 4‑month continuation phase with INH and RIF. This regimen is effective against drug‑susceptible TB, including pulmonary and extrapulmonary forms. The 6‑month duration is endorsed by WHO guidelines for uncomplicated disease.

Second‑Line Regimens

For multidrug‑resistant TB (MDR‑TB) and extensively drug‑resistant TB (XDR‑TB), second‑line agents are incorporated into longer regimens (≥18 months) guided by drug susceptibility testing. Fluoroquinolones, aminoglycosides, linezolid, and cycloserine form the backbone of these regimens, often in combination with bedaquiline or delamanid in XDR‑TB.

Adjunctive Therapy

In tuberculous meningitis, high‑dose rifampin (10 mg kg⁻¹ day⁻¹) and adjunctive corticosteroids are recommended to reduce inflammation. Pyrazinamide and high‑dose INH are also employed to enhance CNS penetration. For pleural TB, therapeutic thoracentesis may be combined with standard anti‑TB therapy.

Off‑Label Uses

Rifampin’s broad antimicrobial spectrum has led to its use in certain non‑tuberculous infections, such as brucellosis and leprosy. Linezolid has been employed off‑label in disseminated mycobacterial infections where other agents are contraindicated. However, evidence for such uses remains limited and requires cautious interpretation.

Adverse Effects

Common Side Effects

• Isoniazid: hepatotoxicity, peripheral neuropathy, hypersensitivity reactions, and drug‑induced fever.
• Rifampin: hepatotoxicity, orange discoloration of body fluids, gastrointestinal upset, and drug interactions via enzyme induction.
• Pyrazinamide: hyperuricemia, hepatotoxicity, and gastrointestinal discomfort.
• Ethambutol: optic neuritis leading to visual disturbances, particularly in patients with pre‑existing ocular disease.

Serious or Rare Adverse Reactions

Serious hepatotoxicity can occur with any first‑line agent, especially INH and RIF. The incidence of rifampin‑induced hepatotoxicity is estimated at 0.3–2 % of patients. Isoniazid‑associated peripheral neuropathy is more frequent in patients with diabetes or malnutrition. Ethambutol‑associated optic neuropathy may manifest as decreased visual acuity or color vision deficits. Aminoglycoside therapy carries a high risk of nephrotoxicity and ototoxicity, with incidence rates approaching 10–30 % in prolonged courses.

Black Box Warnings

INH carries a black box warning for serious hepatic injury, particularly in patients with pre‑existing liver disease, alcohol use, or concomitant hepatotoxic drugs. RIF is also associated with a black box warning for hepatotoxicity, and caution is warranted in hepatic impairment.

Drug Interactions

Enzyme Induction and Inhibition

Rifampin is a potent inducer of hepatic CYP3A4 and UGT enzymes, thereby reducing the plasma concentrations of drugs such as oral contraceptives, warfarin, and certain antiretrovirals. Isoniazid can inhibit CYP2E1, potentially affecting the metabolism of isoniazid‑related hepatotoxicity. Aminoglycosides should be avoided with nephrotoxic agents (e.g., NSAIDs, loop diuretics) to mitigate cumulative renal injury.

Pharmacodynamic Interactions

Co‑administration of fluoroquinolones and benzodiazepines may increase the risk of seizures due to additive CNS penetration. Linezolid’s inhibition of monoamine oxidase can potentiate serotonergic agents, raising the risk of serotonin syndrome.

Contraindications

Patients with severe hepatic impairment (Child‑Pugh C) are generally contraindicated for rifampin and isoniazid unless therapeutic necessity outweighs risk. Aminoglycosides are contraindicated in patients with pre‑existing renal disease or hearing loss. Ethambutol is contraindicated in patients with significant visual impairment or optic nerve disease.

Special Considerations

Pregnancy and Lactation

INH, RIF, and PZA are considered category B drugs in pregnancy, with no definitive evidence of teratogenicity. However, INH can cause neonatal neuropathy if maternal deficiency of pyridoxine is not corrected. RIF has limited placental transfer but may reduce the effectiveness of oral contraceptives in the postpartum period. Lactation is generally considered safe with INH, RIF, and PZA; yet, the potential for infant exposure to RIF via breast milk is low. Ethambutol is usually avoided during pregnancy due to limited data.

Pediatric Considerations

Dosing in children is weight‑based, typically calculated as mg kg⁻¹ day⁻¹. Isoniazid dosing may vary 10–15 mg kg⁻¹ day⁻¹ based on acetylator status. Ethambutol dosing is 15 mg kg⁻¹ day⁻¹, with caution for optic neuropathy. Pediatric patients also benefit from pyridoxine supplementation to mitigate neuropathy risk.

Geriatric Considerations

Older adults exhibit reduced hepatic and renal function, necessitating dose adjustments for INH, RIF, and aminoglycosides. Monitoring for hepatotoxicity and nephrotoxicity is particularly important. Polypharmacy increases the risk of drug interactions, especially with RIF’s enzyme induction.

Renal and Hepatic Impairment

INH’s clearance is largely hepatic but requires adjustment in severe hepatic failure. RIF dosing may be reduced in hepatic impairment, with careful monitoring of liver enzymes. Pyrazinamide and EMB are renally cleared; dosing intervals should be extended in renal impairment to avoid accumulation. Aminoglycosides demand meticulous adjustment based on serum trough concentrations to prevent toxicity.

Summary/Key Points

• First‑line antitubercular therapy relies on a synergistic combination of INH, RIF, PZA, and EMB, with dosing adjustments guided by pharmacokinetic principles.
• Second‑line agents are reserved for drug‑resistant TB and exhibit distinct mechanisms, including DNA gyrase inhibition (fluoroquinolones) and ribosomal blockade (linezolid).
• Hepatotoxicity is the most significant adverse effect, particularly with INH and RIF; routine monitoring of liver enzymes is advised.
• Rifampin’s enzyme induction profile necessitates careful review of concomitant medications to prevent therapeutic failure.
• Special populations—including pregnant women, children, elderly, and patients with organ dysfunction—require individualized dosing regimens and heightened surveillance.

Careful integration of pharmacodynamic understanding, pharmacokinetic data, and patient‑specific factors is essential for optimizing antitubercular therapy and mitigating adverse outcomes.

References

1. Gilbert DN, Chambers HF, Saag MS, Pavia AT. The Sanford Guide to Antimicrobial Therapy. 53rd ed. Sperryville, VA: Antimicrobial Therapy Inc; 2023.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.